Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice

Fig. 1

Kaplan-Meier curves of real-world progression-free survival in a the unadjusted analysis (number of patients at risk are shown), b sIPTW-adjusted analysis (number of patients at risk are shown), and c after PSM. LET, letrozole; NR, not reached; PAL, palbociclib; PSM, propensity score matching; rwPFS, real-world progression-free survival; sIPTW, stabilized inverse probability of treatment weighting

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us